Skip to menu Skip to content Skip to footer
News

Breakthrough treatment for hepatitis C

15 April 2014
Decorative
Professor Darrell Crawford.

A breakthrough treatment for hepatitis C that halves treatment time has been developed in an international clinical trial that included The University of Queensland.  

The landmark study has been published in the New England Journal of Medicine in a paper co-authored by Professor Darrell Crawford, head of the UQ School of Medicine and director of the Gallipoli Medical Research Foundation.Professor Crawford said the findings could have a significant, positive impact on millions of patients living with hepatitis C around the world.

“This treatment regime works in half the amount of time as existing treatments with considerably fewer side-effects,” Professor Crawford said.

“Current hepatitis C treatments include medications administered by injections for 24 to 48 weeks, which often cause many severe side-effects, such as anxiety and depression.

“Treatment in this study was administered orally for only 12 weeks with less than one per cent of trial participants discontinuing due to side-effects.”

The research was conducted at 79 sites across the world, including four in Australia.

The Gallipoli Medical Research Foundation’s Clinical Trials Unit, based at Greenslopes Private Hospital, was the first site to enroll a patient outside the USA.

This was a randomised, double-blind, placebo-controlled trial where all participants had been diagnosed with the hepatitis C virus (HCV) of the type 1 genotype and had not previously taken medications to treat the HCV infection. 

Half the participants received the new treatment regime for 12 weeks while the other half received no treatment.

The groups were then reversed, thereby allowing all participants to be treated with the new drugs.

The new “triple therapy” treatment was taken in combination with ribavirin (RBV).

It is estimated that 130-150 million people worldwide are chronically infected with hepatitis C. (WHO, 2014)

In 2011, about 226,700 people in Australia were living with chronic hepatitis C. (The Kirby Institute, 2012).

Media: Brian Mallon, 07 3365 5254, 040 362 1109, b.mallon@uq.edu.au

Related articles

A man in a lab coat and protective goggles standing in front of a microscope

New ultrasound imaging to map drug delivery into the brain

A new device combining ultrasound and advanced imaging to provide crucial information for the safe delivery of drugs into the brain has been developed by University of Queensland researchers.
14 July 2025
Four cyclists gliding along in the sunrise at the Trapiche in Pelotas, Brazil.

Staying physically active cuts risk of early death by 40 per cent

Adults who stay consistently active throughout their life can lower their risk of early death by up to 40 per cent, a global study led by UQ has found.
11 July 2025

Media contact

Subscribe to UQ News

Get the latest from our newsroom.